Galectin Therapeutics Inc. (GALT): Price and Financial Metrics
GET POWR RATINGS... FREE!
GALT Stock Price Chart Interactive Chart >
GALT Price/Volume Stats
| Current price | $1.32 | 52-week high | $4.40 |
| Prev. close | $1.31 | 52-week low | $1.19 |
| Day low | $1.28 | Volume | 68,200 |
| Day high | $1.35 | Avg. volume | 109,559 |
| 50-day MA | $1.54 | Dividend yield | N/A |
| 200-day MA | $2.45 | Market Cap | 78.39M |
Galectin Therapeutics Inc. (GALT) Company Bio
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company was founded in 2000 and is based in Norcross, Georgia.
Latest GALT News From Around the Web
Below are the latest news stories about Galectin Therapeutics Inc that investors may wish to consider to help them evaluate GALT as an investment opportunity.
NASH (Non-Alcoholic Steatohepatitis) Market to Reach USD 21,879 Million by 2028 - Powered by Increasing Pharmaceutical R&D Expenditure and Escalating Obese Population- Vantage Market ResearchWASHINGTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Non-Alcoholic Steatohepatitis (NASH) Market finds that growing demand for ideal NASH therapeutics is expediting market growth. Primarily driven by increasing pharmaceutical Research and Development (R&D) expenditure, the total global Non-Alcoholic Steatohepatitis (NASH) Market is estimated to reach USD 21,879 Million by 2028, up from USD 1,569 Million in 2021, at a Compound Annual Growth Rate (CAGR) of 60.4%. Furthermore, the escalating obese population across the globe is also anticipated to augment the growth of the Global Non-Alcoholic Steatohepatitis (NASH) Market, states Vantage Market Research, in a report, titled " Non Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitami... |
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect ConferenceNORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. Mr. Joel Lewis, President and Chief Executive Officer, and Dr. Pol F. Boudes, Chief Medical Officer, will be presenting on behalf of the Company. A webcast of this presentation will be available on the "Investor Relations" section under "Events and Presentations" of the Company''s website, https://investor.galectintherapeutics.com , at Full story available on Benzinga.com |
Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. UihleinNORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on the second $10 million convertible note pursuant to a financing agreement entered in September, 2021, with Richard E. Uihlein, the Company’s Chairman and largest individual stockholder. In total, the Company has received $30 million in three convertible notes from Mr. Uihlein in 2021. The convertible |
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual MeetingNAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda, of Johns Hopkins, and Drs. Nishant Agrawal and Ari Rosenberg, both of the University of Chicago Medical Center, engaged to advise on path forward in oncology Cancer immunotherapy efforts likely to focus on Head and Neck cancers Shareholders approved all proposals, including the reelection of its Board of Directors NORCROSS, Ga., Dec. 13, 2021 (G |
-$0.19 Earnings Per Share Expected for Galectin Therapeutics Inc. (NASDAQ:GALT) This QuarterWall Street analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to post earnings of ($0.19) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Galectin Therapeutics earnings. Galectin Therapeutics posted earnings per share of ($0.14) in the same quarter last year, which suggests a negative year-over-year growth rate of 35.7%. The [] |
GALT Price Returns
| 1-mo | -14.84% |
| 3-mo | -29.41% |
| 6-mo | -49.81% |
| 1-year | -66.75% |
| 3-year | -67.33% |
| 5-year | -45.90% |
| YTD | -36.23% |
| 2021 | -7.59% |
| 2020 | -21.68% |
| 2019 | -16.62% |
| 2018 | 2.69% |
| 2017 | 240.82% |
Loading social stream, please wait...